* GeneDx Holdings Corp reported a quarterly adjusted loss of 33 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $-2.44. The mean expectation of four analysts for the quarter was for a loss of 67 cents per share. Wall Street expected results to range from -75 cents to -57 cents per share.
* Revenue rose 41.6% to $61.10 million from a year ago; analysts expected $49.46 million.
* GeneDx Holdings Corp's reported EPS for the quarter was a loss of 78 cents.
* The company reported a quarterly loss of $20.24 million.
* GeneDx Holdings Corp shares had risen by 21.4% this quarter and gained 302.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 11.1% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the healthcare facilities & services peer group is also "buy"
Wall Street's median 12-month price target for GeneDx Holdings Corp is $12.50 This summary was machine generated from LSEG data April 30 at 01:46 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.67 -0.33 Beat
Dec. 31 2023 -0.75 -0.69 Beat
Sep. 30 2023 -1.31 -0.82 Beat
Jun. 30 2023 -1.31 -1.64 Missed
Comments